

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
松井 真 , 中西惠美	免疫修飾治療	祖父江元 , 辻省次	神経疾患治療ストラテジー	中山書店	東京	2017	20-26
長山成美 , 松井 真	多発性硬化症・視神經脊髄炎	門脇孝 , 小室一成 , 宮地良樹	診療ガイドライン UP-To-DATE 2018-2019	メディカルレビュー社	大阪 / 東京	2018	537-541
中西惠美 , 松井 真	MSはどのように診断しますか , 診断ガイドラインにはどのようなものがあり , どう利用すればいいでしょうか	吉良潤一 , 鈴木則宏	中枢脱髓性疾患	中外医学社	東京	2018	190-194
荻野美恵子	MS/NMO の医療費助成、患者負担について教えてください	吉良潤一	中枢脱髓性疾患	中外医学社	東京	2018	404-410
荻野美恵子	神経	工藤翔二蝶 名林直彦、荻野美恵子	内保連グリーンブック「説明と同意」に関する調査報告と提言	内保連	東京	2017	91-93
高田結 , 酒井康成	多発性硬化症	小児内科・小児外科編集委員会共編	小児疾患の診断治療基準	東京医学社	東京	2018	750-751
野村 恒一	【NMO と MS の最新情報】 NMO と MS の急性期治療		脊椎脊髄ジャーナル	三輪書店	東京	2017	755-764
王子 聰, 野村 恒一	【中枢神経系脱髓疾患の最前線-抗 MOG 抗体の関与を考える】視神經脊髄炎関連疾患と抗 AQP4 抗体 免疫治療		Clinical Neuroscience	中外医学社	東京	2018	1316-1320
田島 孝士 , 野村 恒一	【近代脳卒中学の進歩と落とし穴】神経免疫学からみた脳卒中		成人病と生活習慣病	東京医学社	東京	2018	723-729
鈴木 理人 , 野村 恒一	【神経疾患と神経障害性疼痛】末梢神経障害による神経障害性疼痛 病態と治療 急性/慢性炎症性脱髓性多発性神経根障害		Clinical Neuroscience	中外医学社	東京	2019	1356-1358
王子 聰, 野村 恒一	【血液浄化療法 2019】アフェレシス 神経疾患におけるアフェレシス 薬物療法とのすみわけ		腎と透析	東京医学社	東京	2019	469-474
成川 真也 , 野村 恒一	【「しひれ」の原因とメカニズムを学ぶ】足の「しひれ」の鑑別診断		日本医事新報	日本医事新報社	東京	2019	32-37
野村 恒一	【「しひれ」の原因とメカニズムを学ぶ】問診講座 ここがポイント		日本医事新報	日本医事新報社	東京	2019	20-25

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Matsui M.	How to use the new 2017 Japanese guidelines for multiple sclerosis and neuromyelitis optica	Clin Exp Neuroimmunology	8	351-360	2017
Suzuki S, Ishikawa N, et al., Matsui M.	Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan	Neurology	89	1127-1134	2017
Niino M, Fukazawa T, Kira J, Okuno T, Mori M, Sanjo N, Ohashi T, Fukaura H, Fujimori J, Shimizu Y, Mifune N, Miyazaki Y, Takahashi E, Kikuchi S, Langdon D, Benedict RH, Matsui M.	Validation of the Brief International Cognitive Assessment for Multiple Sclerosis in Japan	Mult Scler J-Exp Transl Clin	Oct-Dec	1-8	2017
Niino M, Ohashi T, Ochi H, Nakashima I, Shimizu Y, Matsui M.	Japanese guidelines for dimethyl fumarate	Clin Exp Neuroimmunology	9	235-243	2018
Oono M, Fujita Y, Uchida N, et al., Matsui M.	Rheumatoid meningitis developed in patient with stable rheumatoid arthritis and myasthenia gravis – detailed analysis of intracranial inflammation using flow cytometry	J Neuroinflammation	15 https://doi.org/10.1186/s12974-018-196-3	151	2018
松井 真	多発性硬化症治療薬の理解と選択	神経治療	35	499-503	2018
Niino M, Fukazawa T, Kira JI, Okuno T, Mori M, Sanjo N, Ohashi T, Fukaura H, Fujimori J, Shimizu Y, Mifune N, Miyazaki Y, Takahashi E, Kikuchi S, Langdon D, Benedict RH, Matsui M.	Cognition with magnetic resonance imaging findings and social activities in patients with multiple sclerosis in a Japanese cohort	Clin Exp Neuroimmunology	10	41-48	2019
Ogino M, Okamoto S, Ohta H, Sakamoto M, Nakamura Y, Iwasaki K, Yoshida M, Hiroi S, Kawachi I.	Prevalence, treatments and medical cost of multiple sclerosis in Japan based on analysis of a health insurance claims database.	Clin Exp Neuroimmunol.	8	318-326	2017

Nishida Y, Takahashi YK, Kanai T, Nose Y, Ishibashi S, Sanjo N, Uzawa A, Oda F, Ozawa Y, <u>Kuwabara S</u> , Noguchi E, Suzuki S, Nakahara J, Suzuki N, Ogawa T, Yokoyama K, Hattori N, Konno S, Fujioka T, Kawaguchi N, Hatanaka Y, Sonoo M, Kaneko J, <u>Ogino M</u> , Nishiyama K, Nomura K, <u>Yokota T.</u>	Safety of tapering tacrolimus dose in patients with well-controlled anti-acetylcholine receptor antibody-positive myasthenia gravis.	Eur J Neurol.	27	100-104	2020
Matsui N, Nodera H, Kuzume D, Iwasa N, Unai Y, Sakai W, Miyazaki Y, Yamazaki H, Osaki Y, Furukawa T, Yamasaki M, <u>Izumi Y</u> , Kusunoki S, Arisawa K, <u>Kaji R.</u>	Guillain-Barré syndrome in a local area in Japan, 2006-2015:An epidemiological and clinical study of 108 patients.	Eur J Neurol	25	718-724	2018
Muto K, Matsui N, Unai Y, Sakai W, Hajiri S, Ueda K, Miki H, Furukawa T, Abe M, <u>Kaji R</u>	Memory B cell resurgence requires repeated rituximab in myasthenia gravis.	Neuromuscular Disorders	27	918-922	2017
<u>Izumi Kawachi</u>	Neuropathological features of “non-motor” symptoms in multiple sclerosis and neuromyelitis optica	Clinical and experimental neuroimmunology	10	161-168	2019
勇亞衣子, 河内泉	肥厚性硬膜炎の歴史と概念—新たな診断基準	脳神経内科	91	340-351	2019
Nishihara H, Shimizu F, Kitagawa T, Yamanaka N, Akada J, Kuramitsu Y, Sano Y, Takeshita Y, Maeda T, Abe M, Koga M, Nakamura K, <u>Kanda T.</u>	Identification of galectin-3 as a possible antibody target for secondary progressive multiple sclerosis.	Mult Scler	23(3)	382-394	2017
Takahashi S, Maeda T, Sano Y, Nishihara H, Takeshita Y, Shimizu F, <u>Kanda T.</u>	Active form of vitamin D directly protects the blood-brain barrier in multiple sclerosis	Clin Exp Neuroimmunol	8(3)	244-254	2017
Koga M, Kishi M, Fukusako T, <u>Kanda T.</u>	Distal limb weakness phenotype of Guillain-Barré syndrome.	J Neurol Sci	392	83-88	2018

Shimizu F, Takeshita Y, Sano Y, Hamamoto Y, Shiraishi H, Sato T, Yoshimura S, Maeda T, Fujikawa S, Nishihara H, Kitanosono H, Tsujino A, <u>Motomura M, Kanda T.</u>	GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome.	Brain	142	2253-2264	2019
Shimizu F, Takeshita Y, Hamamoto Y, Nishihara H, Sano Y, Honda M, Sato R, Maeda T, Takahashi T, Fujikawa S, <u>Kanda T.</u>	GRP 78 antibodies are associated with clinical phenotype in neuromyelitis optica	Ann Clin Transl Neurol	6	2079-2087	2019
Shimizu F, Oishi M, Sawai S, Beppu M, Misawa S, Matsui N, Miyashiro A, Maeda T, Takeshita Y, Nishihara H, Sano Y, Sato R, Kaji R, <u>Kuwabara S, Kanda T.</u>	Increased IP-10 production by blood-nerve barrier in multifocal acquired demyelinating sensory and motor neuropathy and multifocal motor neuropathy.	J Neurol Neurosurg Psychiatry	90	444-450	2019
Hayashida S, Masaki K, Yonekawa T, Suzuki SO, Hiwatashi A, Matsushita T, Watanabe M, Yamasaki R, Suenaga T, Iwaki T, Murai H, <u>Kira J-I.</u>	Early and extensive spinal white matter involvement in neuromyelitis optica.	Brain Pathology	27	249-	2017
Koji Shinoda, Takuya Matsushita, Yuri Nakamura, Katsuhisa Masaki, Ryo Yamasaki, Hiroo Yamaguchi, Osamu Togao, Akio Hiwatashi, <u>Jun-ichi Kira.</u>	HLA-DRB1*04:05 allele is associated with intracortical lesions on three-dimensional double inversion recovery images in Japanese patients with multiple sclerosis.	Multiple Sclerosis Journal	24	710	2018
Guzailiayi Maimaitijiang, Koji Shinoda, Yuri Nakamura, Katsuhisa Masaki, Takuya Matsushita, Noriko Isobe, Ryo Yamasaki, Yasunobu Yoshikai, <u>Jun-ichi Kira.</u>	Association of Decreased Percentage of Vδ2+Vγ9+ γδ T Cells with Disease Severity in Multiple Sclerosis.	Frontiers in Immunology	9	748	2018

<u>Yuri Nakamura, Laura Gaetano, Takuya Matsushita, Altermatt Anna, Till Sprenger, Ernst-Wilhelm Radue, Jens Wuerfel, Lorena Bauer, Michael Amann, Koji Shinoda, Noriko Isobe, Ryo Yamasaki, Takahiko Saida, Ludwig Kappos, Jun-ichi Kira</u>	A comparison of brain magnetic resonance imaging lesions in multiple sclerosis by race with reference to disability progression	Journal of Neuroinflammation	15	255	2018
<u>Takayuki Fujii, Ryo Yamasaki, Kyoko Iinuma, Daisuke Tsuchimoto, Yoshihiro Hayashi, Ban-yu Saitoh, Takuya Matsushita, Mizuho A Kido, Shinichi Aishima, Hiroshi Nakanishi, Yusaku Nakabeppu, Jun-ichi Kira</u>	A Novel Autoantibody against Plexin D1 in Patients with Neuropathic Pain.	Annals of Neurology	84	208	2018
<u>Jun-ichi Kira and Noriko Isobe.</u>	Helicobacter pylori infection and demyelinating disease of the central nervous system	Journal of Neuroimmunology	329	14	2019
<u>Ayako Sakoda, Takuya Matsushita, Yuri Nakamura, Mitsuru Watanabe, Koji Shinoda, Katsuhisa Masaki, Ryo Yamasaki, Jun-ichi Kira</u>	Environmental risk factors for multiple sclerosis in Japanese people.	Multiple Sclerosis and Related Disorders	38	101872	2019
<u>Guzailiayi Maimaitijiang, Mitsuru Watanabe, Koji Shinoda, Noriko Isobe, Yuri Nakamura, Katsuhisa Masaki, Takuya Matsushita, Yasunobu Yoshikai, Jun-ichi Kira</u>	Long-term use of interferon- β in multiple sclerosis increases V81 $^{-}$ V82 $^{-}$ V γ 9 $^{-}$ $\gamma\delta$ T cells that are associated with a better outcome.	Journal of Neuroinflammation	16	179	2019

Mitsuru Watanabe, Yuri Nakamura, Zuzanna Michalak,Noriko Isobe, Christian Barro, Takuya Matsushita, Fumie Hayashi, Ryo Yamasaki, Jens Kuhle, <u>Jun-ichi Kira</u>	Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.	Neurology	93	e1299	2019
Yuri Nakamura, Zhewen Liu, Shoko Fukumoto, Koji Shinoda, Ayako Sakoda, Takuya Matsushita, Shotaro Hayashida, Noriko Isobe, Akio Hiwatashi, Ryo Yamasaki, <u>Jun-ichi Kira</u>	Spinal cord involvement by atrophy and associations with disability are different between multiple sclerosis and neuromyelitis optica spectrum disorder	European Journal of Neurology	27	92	2020
Kuwahara M, Suzuki H, Oka N, Ogata H, Yanagimoto S, Sadakane S, Fukumoto Y, Yamana M, Yuhara Y, Yoshikawa K, Morikawa M, Kawai S, Okazaki M, Tsujimoto T, Kira JI, Kusunoki S.	Electron microscopic abnormality and therapeutic efficacy in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin155 immunoglobulin G4 antibody.	Muscle Nerve	57	498-502	2018
Yoshikawa K, Kuwahara M, Morikawa M, Fukumoto Y, Yamana M, Yamagishi Y, <u>Kusunoki S.</u>	Varied antibody reactivities and clinical relevance in anti-GQ1b antibody-related diseases.	Neurol Neuroimmunol Neuroinflamm	5	e501	2018
<u>Kuwahara M,</u> <u>Kusunoki S.</u>	Mechanism and spectrum of anti-glycolipid antibody-mediated chronic inflammatory demyelinating polyneuropathy.	Clin Exp Neuroimmunol	9	65-74	2018
Miyamoto K, <u>Fujihara K, Kira JI,</u> <u>Kuriyama N,</u> <u>Matsui M,</u> Tamakoshi A, <u>Kusunoki S.</u>	Nationwide epidemiological study of neuromyelitis optica in Japan.	J Neurol Neurosurg Psychiatry	89	667-668	2018
Fukumoto Y, Kuwahara M, Kawai S, Nakahama K, <u>Kusunoki S.</u>	Acute demyelinating polyneuropathy induced by nivolumab.	J Neurol Neurosurg Psychiatry	89	435-437	2018

Yamana M, Kuwahara M, Fukumoto Y, Yoshikawa K, Takada K, <u>Kusunoki S.</u>	Guillain-Barré syndrome and related diseases after influenza virus infection.	Neurol Neuroimmunol Neuroinflamm	6	e575	2019
Yamagishi Y, Samukawa M, Kuwahara M, Takada K, Saigoh K, Mitsui Y, Oka N, Hashiguchi A, Takashima H, <u>Kusunoki S.</u>	Charcot-Marie-Tooth disease with a mutation in FBLN5 accompanying with the small vasculitis and widespread onion-bulb formations.	J Neurol Sci	410	116623 [Online ahead of print]	2020
Matsui T, Hamada Y, Kuwahara M, Morise J, Oka S, Kaida K, <u>Kusunoki S.</u>	Association of variability in antibody binding affinity with a clinical course of anti-MAG neuropathy.	J Neuroimmunol	339	577127	2020
Suichi T, Misawa S, Sato Y, Beppu M, Sakaida E, Sekiguchi Y, Shibuya K, Watanabe K, Amino H, <u>Kuwabara S.</u>	Proposal of new clinical diagnostic criteria for POEMS syndrome.	J Neurol Neurosurg Psychiatry	90	133-137	2019
Kurokawa M, Torio M, Ohkubo K, Tocan V, Ohyama N, Toda N, Ishii K, Nishiyama K, Mushimoto Y, Sakamoto R, Nakaza M, Horie R, Kubota T, Takahashi MP, <u>Sakai Y*</u> , Nomura M, Ohga S.	The expanding phenotype of hypokalemic periodic paralysis in a Japanese family with p.Val876Glu mutation in <i>CACNA1S</i> .	Mol Genet Genomic Med	In press		2020
Kinoshita K, Ishizaki Y, Yamamoto H, Sonoda M, Yonemoto K, Kira R, Sanefuji M, Ueda A, Matsui H, Ando Y, <u>Sakai Y*</u> , Ohga S.	<i>De novo</i> p.G696S mutation in <i>COL4A1</i> causes intracranial calcification and late-onset cerebral hemorrhage: A case report and review of the literature.	Eur J Med Genet	In press		2019
Nanishi E, Hoshina T, Sanefuji M, Kadoya R, Kitazawa K, Arahata Y, Sato T, Hirayama Y, Hirai K, Yanai M, Nikaido K, Maeda A, Torisu H, Okada K, <u>Sakai Y</u> , Ohga S	A nationwide survey of pediatric-onset Japanese encephalitis in Japan	Clin Infect Dis	68	2099-2104	2019

Okuzono S, Fukai R, Noda M, Miyake N, Leea S, Kaku N, Sakata A, Sanefuji M, Akamine S, Kanno S, Ishizaki Y, Torisu H, Kira R, Matsumoto N, <u>Sakai Y*</u> , Ohga S.	An acute encephalopathy with reduced diffusion in BRAF-associated cardio-facio-cutaneous syndrome.	Brain Dev	41	378-381	2019
Akamine S, Sagata N, <u>Sakai Y</u> , Kato TA, Nakahara T, Matsushita Y, Togao O, Hiwatashi, A, Sanefuji, M, Ishizaki Y, Torisu H, Saitsu H, Matsumoto N, Hara T, Sawa A, Kano S, Furue M, Kanba S, Shaw CA, Ohga S.	Early-onset epileptic encephalopathy and severe developmental delay in an association with de novo double mutations in NF1 and MAGEL2.	Epilepsia Open	In press		2018
Ichimiya Y, Kaku N, <u>Sakai Y</u> , Yamashita F, Matsuoka W, Muraoka M, Akamine S, Mizuguchi S, Torio M, Motomura Y, Hirata Y, Ishizaki Y, Sanefuji M, Torisu H, Takada H, Maehara Y, Ohga S.	Transient dysautonomia in an acute phase of encephalopathy with biphasic seizures and late reduced diffusion.	Brain Dev	39	621-624	2017
Ikenaga C, Kubota A, Kadoya M, Taira K, Uchio N, Hida A, Maeda MH, Nagashima Y, Ishiura H, Kaida K, Goto J, Tsuji S, Shimizu J	Clinicopathologic features of myositis patients with CD8-MHC-1 complex pathology	Neurology	58(10)	1060-1068	2017
Uchio N, Taira K, Ikenaga C, Unuma A, Kadoya M, Toda T, Shimizu J	Granulomatous myositis induced by anti-PD-1 monoclonal antibodies	Neurol Neuroimmunol Neuroinflamm	5	e464	2018
Uchio N, Taira K, Ikenaga C, Kadoya M, Unuma A, Yoshida K, Nakatani-Enomoto S, Hatanaka Y, Sakurai Y, Shioi Y, Kaida K, Kubota A, Toda T, Shimizu J	Inflammatory myopathy with myasthenia gravis: Thymoma association and polymyositis pathology	Neurol Neuroimmunol Neuroinflamm	6	e535	2019

Ikeguchi R, Shimizu Y, Abe K, Shimizu S, Maruyama T, Nitta M, Abe K, Kawamata T, Kitagawa .	Proton magnetic resonance spectroscopy differentiates tumefactive demyelinating lesions from gliomas.	Multiple Sclerosis and Related Disorders	26	77-84	2018
Ikeguchi R, Shimizu Y, Shimizu S, Kitagawa K.	CSF and clinical data are useful in differentiating CNS inflammatory demyelinating disease from CNS lymphoma.	Mult Scler.	24 (9)	1212-1223	2018
Nishimura A, Ikeguchi R, Kobayashi M, Takeuchi M, Shimizu Y, Saigusa H, Kitagawa K.	Chronic sarcoid myopathy manifesting only as dysphagia and dysarthria in an 84-year old woman .	Clin Neurol Neurosurg	173	58-60	2018
Shimizu Y.	High priced drugs for multiple sclerosis and medical economy in Clinical and Experimental Neuroimmunology Japan	Clinical and Experimental Neuroimmunology	8 (4)	289 - 291	2017
Shimizu Y, Ikeguchi R, Kitagawa K	When and how disease-modifying drugs for multiple sclerosis should be changed in daily practice	Clinical and Experimental Neuroimmunology	8 (1)	71 - 80	2017
田中正美、清水優子	多発性硬化症へのフルマロ酸ジメチル治療	Brain and Nerve	69 (9)	1041-1046	2017
Hokkoku K, Matsukura K, Uchida Y, Kuwabara M, Furukawa Y, Tsukamoto H, Hatanaka Y, Sonoo M.	Quantitative muscle ultrasound is useful for evaluating secondary axonal degeneration in chronic inflammatory demyelinating polyneuropathy.	Brain and Behavior	7 (10)	e00812	2017
Kanbayashi T, Yamauchi T, Miyaji Y, Sonoo M.	Investigation of anodal stimulation and its implications for F-wave examinations.	Muscle Nerve	56 (1)	51-6	2017
Higashihara M, Sonoo M, Ishiyama A, et al	Quantitative Analysis of Surface Electromyography for Pediatric Neuromuscular Disorders.	Muscle Nerve	58 (6)	824-827	2018
Sonoo M	Far-field potentials in the compound muscle action potential.	Muscle Nerve	61 (3)	271-9	2020
Ikeda S, Koike H, Nishi R, Kawagashira Y, Iijima M, Katsuno M, Sobue G.	Clinicopathological characteristics of subtypes of chronic inflammatory demyelinating polyradiculoneuropathy.	J Neurol Neurosurg Psychiatry	90(9)	988-996	2019
Koike H, Katsuno M, Sobue G.	New teased-fibre definitions represent specific mechanisms of neuropathy.	J Neurol Neurosurg Psychiatry	90(2)	124	2019
Koike H, Nishi R, Ikeda S, Kawagashira Y, Iijima M, Katsuno M, Sobue G.	Ultrastructural mechanisms of macrophage-induced demyelination in CIDP.	Neurology	91(23)	1051-1060	2018

Koike H, Kadoya M, Kaida K, Ikeda S, Kawagashira Y, Iijima M, Kato D, Ogata H, Yamasaki R, Matsukawa N, Kira JI, Katsuno M, <u>Sobue G.</u>	Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin 155 and anti-contactin 1 antibodies.	J Neurol Neurosurg Psychiatry.	88	465-73	2017
Takahashi M, Koike H, Ikeda S, Kawagashira Y, Iijima M, Hashizume A, Katsuno M, <u>Sobue</u> <u>G.</u>	Distinct pathogenesis in non-systemic vasculitic neuropathy and microscopic polyangiitis.	Neurol Neuroimmunol Neuroinflamm.	4	e407	2017
Kawagashira Y, Koike H, Kawabata K, Takahashi M, Ohyama K, Hashimoto R, Iijima M, Katsuno M, <u>Sobue</u> <u>G.</u>	Vasculitic neuropathy following exposure to a glyphosate-based herbicide.	Intern Med.	56	1431-4	2017
Noda S, Koike H, Maeshima S, Nakanishi H, Iijima M, Matsuo K, Kimura S, Katsuno M, <u>Sobue G.</u>	Transforming growth factor- β signaling is upregulated in sporadic inclusion body myositis.	Muscle Nerve.	55	741-7	2017
<u>Masayuki Tahara,</u> Tomoko Oeda, Kazumasa Okada, Takao Kiriyama, Kazuhide Ochi, Professor Hirofumi Maruyama, Hikoaki Fukaura, Professor Kyoichi Nomura, Professor Yuko Shimizu, Masahiro Mori, Professor Ichiro Nakashima, Tatsuro Misu, Atsushi Umemura, Kenji Yamamoto, Hideyuki Sawada.	Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multi-centre, randomised, double-blind, placebo-controlled trial.	The Lancet Neurology	19	298-306	2020
田原将行	進行性多巣性白質脳症のマネージ メント	BIO Clinica	34 (5)	80-85	2019

Koda T, Namba A, <u>Nakatsuji Y</u> , Niino M, Miyazaki Y, Sugimoto T, Kinoshita M, Takata K, Yamashita K, Shimizu M, Fukazawa T, Kumanogoh A, Mochizuki H, Okuno T.	Beneficial effects of fingolimod in MS patients with high serum Sema4A levels.	PLoS ONE	15(1)	125	2018
Niino M, Miyazaki Y	Radiologically isolated syndrome and clinically isolated syndrome	Clin Exp Neuroimmunol	8 (Suppl. 1)	24-32	2017
Miyazaki Y, <u>Niino M</u> , Takahashi E, et al.	Fingolimod induces BAFF and expands circulating transitional B cells without activating memory B cells and plasma cells in multiple sclerosis.	Clin Immunol	187	95-101	2018
Niino M, Miyazaki Y.	Disease-modifying drugs for multiple sclerosis in Japan: A focus on the 2017 Japanese guidelines and the 2018 supplement.	Clin Exp Neuroimmunol	10(Suppl . 1)	49-53	2019
Niino M, Miyazaki Y.	Cognitive impairment as one of the important non-motor symptoms in multiple sclerosis and neuromyelitis optica spectrum disorders.	Clin Exp Neuroimmunol	10	152-160	2019
Izaki S, Tanaka S, Oji S, Kubota A, Fukaura H, Nakayama M, Nomura K	Association between peripheral plasmablasts and postoperative exacerbation in patients with thymoma-associated myasthenia gravis	Clinical and Experimental Neuroimmunolog y	10 (2)	110-117	2019
Fujihara K, Sato DK, Nakashima I, Takahashi T, Kaneko K, Ogawa R, Akaishi T, Matsumoto Y, Takai Y, Nishiyama S, Kuroda H, Misu T, M Aoki.	MOG-IgG-associated disease: an overview.	Clin Exp Neuroimmunol	9(Suppl. 1)	48-55	2018
Kim SM, Kim SJ, Lee HJ, Kuroda H, Palace J, <u>Fujihara K</u> .	Differential diagnosis of neuromyelitis optica spectrum disorders.	Ther Adv Neurol Disord	Jul;10(7)	265-289	2017

Nishiyama S, Misu T, Shishido-Hara Y, Nakamichi K, Saijo M, Takai Y, Takei K, Yamamoto N, Kuroda H, Saito R ⁵ , Watanabe M, Tominaga T, Nakashima I, <u>Fujihara K</u> , Aoki M.	Fingolimod-associated PML with mild IRIS in multiple sclerosis: a clinicopathological study.	Neurol Neuroimmunol Neuroinflamm	5 (1)	e415	2018
Kaneko K, Sato DK, Nakashima I, Ogawa R, Akaishi T, Takai Y, Nishiyama S, Takahashi T, Misu T, Kuroda H, MD1), Tanaka S, Nomura K, Yuji Hashimoto Y, Callegaro D, Steinman L, <u>Fujihara K</u> , Aoki M	CSF cytokine profile in MOG-IgG+neurologic disease is similar to AQP4-IgG+NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications.	J Neurol Neurosurg Psychiatry	89	927-936	2018
Shosha E, Dubey D, Palace J, Nakashima I, MD, Jacob A, <u>Fujihara K</u> , Takahashi T, Whittam D, Leite MI, Misu T, Takai Y, Messina S, Elsone L, Majed M, Flanagan E, Gadoth A, Huebert C, Sagen J, Greenberg BM, Levy M, Banerjee A, Weinshenker B, Pittock SJ	Area Postrema Syndrome: Frequency, Criteria and Severity in AQP4-IgG positive NMOSD.	Neurology	91	e1642-e1651	2018
Hillebrand S, Schanda K, Nigritinou M, Tsymala I, Böhm D, Peschl P, Bauer J, Takai T, <u>Fujihara K</u> , Nakashima I, Misu T, Reindl M, Lassmann H, Bradl M	Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat.	Acta Neuropathol	137	467-485	2018
Misu T, <u>Fujihara K</u>	NMO spectrum and MOG-antibody-related disseminated encephalomyelitis.	Clin Exp Neuroimmunol	10	9-17	2019
Fujimori J, <u>Fujihara K</u> , Ogawa R, Baba T, Wattjes M, Nakashima I	Patterns of regional brain volume loss in multiple sclerosis: a cluster analysis.	J Neurol	267	395-405	2020

<u>Fujihara K</u>	MOG-antibody-associated disease is different from MS and NMOSD and should be classified as a distinct disease entity - Commentary.	Mult Scler		1352458 5198952 36	2019
<u>Fujihara K</u>	Neuromyelitis optica spectrum disorders: still evolving and broadening	Curr Opin Neurol	32	385-394	2019
<u>Murai H, Nagane Y, Suzuki S, Imai T, Motomura M, Utsugisawa K</u>	Significance of follow-up thoracic imaging in myasthenia gravis	Clin Exp Neuroimmunol	9	246-250	2018
北之園寛子,本村政勝,富田祐輝,岩永洋,岩永直樹,入江隆,白石裕一,辻野彰	ランバートン・イートン筋無力症候群を合併する傍腫瘍性小脳変性症がん治療が著効した1症例報告と本邦PCD-LEMS症例の系統的文献検索	BRAIN and NERVE	71巻2号	167-174	2019
Kimura, Kimitoshi Hohjoh, Hirohiko Fukuoka, Masashi Sato, Wakiro Oki, Shinji Tomi, Chiharu Yamaguchi, Hiromi Kondo, Takayuki Takahashi, Ryosuke Yamamura, Takashi	Circulating exosomes suppress the induction of regulatory T cells via let-7i in multiple sclerosis	Nature Communications	Vol.9 Issue 1	17	2018
Daiki Takewaki, Youwei Lin, Wakiro Sato, Hirohiko Ono, Masakazu Nakamura, Manabu Araki, Tomoko Okamoto, Yuji Takahashi, Yukio Kimura, Miho Ota, Noriko Sato, <u>Takashi Yamamura</u>	Normal brain imaging accompanies neuroimmunologically justified, autoimmune encephalomyelitis	Neurology-Neuroimmunology Neuroinflammation	5(3)	e456	2018
Iwasaa K, <u>Yoshikawa H, Hamaguchi T, Sakai K, Shinohara-Noguchi M, Samuraki M, Takahashia,K, Yanasea,D, Ono K, Ishidaa,C, Yoshitaa,M, Nakamura H, Yamada M.</u>	Time-series analysis: variation of anti-acetylcholine receptor antibody titer in myasthenia gravis is related to incidence of <i>Mycoplasma pneumoniae</i> and influenza virus infections	Neurological Research	40	102-109	2018
渡邊 修	電位依存性カリウムチャネル (VGKC)複合体抗体関連疾患 up to date	BRAIN and NERVE	70 (4)	315-328	2018

Angela Vincent, Philippa Pettingill, Rosie Pettingill, Bethan Lang, Ron Birch, Patrick Waters, Sarosh Irani, Camilla Buckley, <u>Osamu Watanabe</u> , Kimiyoshi Arimura, Matthew C. Kiernan	Association of Leucine-Rich Glioma Inactivated Protein 1, Contactin-Associated Protein 2, and Contactin 2 Antibodies With Clinical Features and Patient-Reported Pain in Acquired Neuromyotonia.	JAMA Neurol.	75 (12)	1519-1527	2018
--	--	--------------	---------	-----------	------